Antibiotics are effective at killing pneumococcus – the cause of about 50 percent of pneumonias – but as it dies the bacterium releases potentially lethal toxins.
Adding an agonist that mimics the action of growth hormone-releasing hormone – which ultimately enables growth – may stop that second wave, according to research published in the Proceedings of the National Academy of Sciences.
"You have to take antibiotics, if you don't, the bugs will grow and you most likely will die anyway," said Dr. Rudolf Lucas, vascular biologist at the Medical College of Georgia at Georgia Health Sciences University.
Problems start when a bacterium that causes pneumonia, in this case pneumococcus, is inhaled. Symptoms include mucus buildup, cough, fever, chills and shortness of breath. Antibiotics are the front line treatment to kill the infection.
An unfortunate result of bacterium death is release of pneumolysin, a toxin that can trigger formation of holes in the walls of the millions of tiny air sacs and blood vessels in the lungs. The result is that fluid, blood and other products find their way into air sacs that were intended for oxygen exchange.
"It's like making a hole in a bucket," said Lucas. He and Dr. Andrew V. Schally, Distinguished Leonard M. Miller Professor of Pathology & Professor of Hematology/Oncology at the University of Miami Miller School of Medicine, are co-corresponding authors on the study.
Pneumolysin naturally binds to cholesterol, a component of all cell membranes including cells lining the air sacs, or alveoli. Once attached to the membrane, the toxin produces complexes that make holes in the membranes of the air sacs before escaping to do similar damage to nearby capillaries. While the close proximity of capillaries normally enables air sacs to replenish blood with oxygen and to remove carbon dioxide, the now open exchange enables fluid and cells from the capillaries to penetrate air sacs as well as the space in between them. To make matters worse, the toxin also blocks a protective sodium uptake system in the lungs that can help remove fluids. Within a few days, the patient is back in jeopardy. "These patients are being treated with an antibiotic and aggressive intensive care support and they (can) still die," Lucas said.
Schally, a Nobel Prize recipient for his discovery of hypothalamic hormones and Head of The Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center in Miami, developed the agonist that may one day make the difference for these patients. The agonist was previously shown to help protect heart muscle in the aftermath of a heart attack.
Surprisingly, GHSU scientists detected receptors for growth hormone releasing hormone in cells lining the air sacs. Typically, growth hormone-releasing hormone is produced by the hypothalamus then goes to the pituitary which makes and releases growth hormone. "We were asking ourselves, what is it doing there?" Lucas said.
They got a clue when they applied the agonist to the growth hormone-releasing hormone in an animal model of pneumonia as well as human lung cells in culture: leaking was significantly reduced and beneficial sodium uptake was restored. Conversely, when they applied a hormone antagonist – to block its action – lung cells became leaky even without toxin exposure, further indicating the hormone's apparent role in protecting the lining of the air sacs and capillaries.
"This is an acute problem; dangerous lung fluid accumulation occurs within days in patients," said Lucas who anticipates the agonist, or a compound with a similar function, could someday be given to patients in those first few critical days to avoid the second onslaught.
As a result of the findings, extensive collaborative studies are being planned on the use of growth hormone-releasing hormone agonists to prevent edema in patients with bacterial pneumonia. Next steps include pursing a National Institutes of Health grant with Dr. Michael A. Matthay, Senior Associate, Cardiovascular Research Institute, University of California, San Francisco, to support more studies that include an isolated human lung model and a preclinical model of laboratory animals who follow the same course as patients: they are infected with the bacterium then given an antibiotic. In the model for the PNAS study, scientists gave the resulting toxin directly.
Dr. Trinad Chakraborty, Dean of the Faculty of Medicine at the University of Giessen in Germany, developed the purified toxin used for the study. Study co-authors Dr. Richard White, GHSU pharmacologist, showed restoration of sodium uptake, and Dr. Supriya Sridhar, GHSU research associate, performed the cell permeability experiments. University of Miami co-authors included Dr. Norman L. Block, Professor of Pathology, Urology, Oncology and Biomedical Engineering, as well as Dr. Ferenc G. Rick, Assistant Research Professor of Pathology.
Toni Baker | EurekAlert!
A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital
Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München
More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.
Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...
Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.
"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...
The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.
Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...
The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...
Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.
Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...
20.04.2017 | Event News
18.04.2017 | Event News
03.04.2017 | Event News
24.04.2017 | Physics and Astronomy
24.04.2017 | Materials Sciences
24.04.2017 | Life Sciences